Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.

O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I.

Am J Hematol. 2018 Nov;93(11):1318-1326. doi: 10.1002/ajh.25243. Epub 2018 Oct 20.

PMID:
30094870
2.

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies.

Faia K, White K, Murphy E, Proctor J, Pink M, Kosmider N, McGovern K, Kutok J.

PLoS One. 2018 Aug 1;13(8):e0200725. doi: 10.1371/journal.pone.0200725. eCollection 2018.

3.

Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity.

Peluso MO, Campbell VT, Harari JA, Tibbitts TT, Proctor JL, Whitebread N, Conley JM, White KF, Kutok JL, Read MA, McGovern K, Faia KL.

PLoS One. 2014 Mar 7;9(3):e90534. doi: 10.1371/journal.pone.0090534. eCollection 2014.

4.

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.

Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL.

Chem Biol. 2013 Nov 21;20(11):1364-74. doi: 10.1016/j.chembiol.2013.09.017. Epub 2013 Nov 7.

5.

Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors.

Jimeno A, Weiss GJ, Miller WH Jr, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM.

Clin Cancer Res. 2013 May 15;19(10):2766-74. doi: 10.1158/1078-0432.CCR-12-3654. Epub 2013 Apr 10.

6.

The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway.

Smith S, Hoyt J, Whitebread N, Manna J, Peluso M, Faia K, Campbell V, Tremblay M, Nair S, Grogan M, Castro A, Campbell M, Ferguson J, Arsenault B, Nevejans J, Carter B, Lee J, Dunbar J, McGovern K, Read M, Adams J, Constan A, Loewen G, Sydor J, Palombella V, Soglia J.

Xenobiotica. 2013 Oct;43(10):875-85. doi: 10.3109/00498254.2013.780671. Epub 2013 Mar 25.

PMID:
23527529
7.

Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists.

Tremblay MR, Nevalainen M, Nair SJ, Porter JR, Castro AC, Behnke ML, Yu LC, Hagel M, White K, Faia K, Grenier L, Campbell MJ, Cushing J, Woodward CN, Hoyt J, Foley MA, Read MA, Sydor JR, Tong JK, Palombella VJ, McGovern K, Adams J.

J Med Chem. 2008 Nov 13;51(21):6646-9. doi: 10.1021/jm8008508. Epub 2008 Oct 9.

PMID:
18842035
8.

IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.

Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T.

Nat Immunol. 2003 May;4(5):491-6.

PMID:
12692549
9.

Supplemental Content

Loading ...
Support Center